NDA 022119 · Feinstein
Ammonia N 13
Ammonia N-13 · Intravenous · Radioactive Diagnostic Agent
NovelLast checked: Nov 21, 2026Latest source record: Jan 5, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Aug 23, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
0 Phase 3, 2 recruiting
FAERS reports
57
43 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 30, 2019.
Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- AMMONIA N 13 · AMMONIA N-13 30mCi-300mCi/8ML (3.75-37.5mCi/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ammonia N-13" as an intervention, any sponsor and status, largest first.
Centre hospitalier de l'Université de Montréal (CHUM)Academic, hospital or other
NCT03275584 · 20,000 participants (planned) · Start Jan 30, 2018 · Primary completion Jan 2028
Drug: N-13 ammonia intravenous injection · For: N-13 Ammonia Safety
Sites: Montreal, Canada
University of MichiganAcademic, hospital or other
NCT01433705 · 70 participants · Start Nov 2011 · Primary completion Jan 19, 2018
Drug: Regadenoson · For: Heart Disease
Sites: Ann Arbor, Michigan
St. Jude Children's Research HospitalAcademic, hospital or other
NCT05583721 · 40 participants (planned) · Start Oct 10, 2023 · Primary completion Sep 2027
Drug: [13N]NH3; Lexiscan · For: Sickle Cell Disease
Sites: Memphis, Tennessee
Ottawa Heart Institute Research CorporationAcademic, hospital or other
NCT03344159 · 15 participants · Start Apr 1, 2018 · Primary completion Aug 30, 2022
Drug: Spironolactone; Placebo · For: Chronic Right-Sided Heart Failure; Pulmonary Arterial Hypertension; Pulmonary Hypertension, Primary, 2 and 3 more
Sites: Ottawa, Canada
Mayo ClinicAcademic, hospital or other
NCT01370265 · 12 participants · Start Feb 2011 · Primary completion Feb 2012
Drug: Regadenoson; Adenosine and 1 more · For: Coronary Artery Disease
Sites: Rochester, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug abuse7
- cough6
- depression6
- drug ineffective6
- chest pain5
- dyspnoea5
- nausea5
- suicide attempt5
- vomiting5
- accidental exposure to product4
- drug hypersensitivity4
- eye irritation4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 3 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 9 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Feinstein
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.